finmarketnews.com
news-details
Health,Dividend

Ex-Dividend Dates Coming This Week: HealthTech Dividend Stocks

May 18th, 2022 

 

From the desk of The Editor

 

Dear Reader,

 

HealthTechMovers.com has identified several healthtech stocks which are expected to go “Ex-Dividend” very soon.  Remember, if you purchase a stock on its ex-dividend date or after, you will not receive the next dividend payment. Instead, the seller gets the dividend. If you purchase before the ex-dividend date, you get the dividend.

 

If you sell your stock before the ex-dividend date, you also are selling away your right to the stock dividend. 

 

So please keep this in mind.

 

Below is our latest Dividend Report:


Laboratory
Symbol: LH
Recent Price: $$247.03
Average Analyst Price Target: $312.20 (26.38%)
Market Cap: $$22.90B
Expected Ex-Dividend Date: May 18 2022
Expected Payment Date: Jun 09 2022
Expected Dividend & Yield: 0.30%

Recent Analyst Action: Eric Coldwell, analyst at Robert W. Baird, reiterates coverage on Laboratory (LH) in the Healthcare sector with a Buy rating and a price target of $ 325 (6 days ago). 

Click for full story >>
--------------------------------------------------------------------------

Select Medical
Symbol: SEM
Recent Price: $$25.18
Average Analyst Price Target: $35.67 (41.69%)
Market Cap: $$3.29B
Expected Ex-Dividend Date: May 18 2022
Expected Payment Date: Jun 01 2022
Expected Dividend & Yield: 1.94%

Recent Analyst Action: Nick Giovacchini, analyst at Credit Suisse, reiterates coverage on Select Medical (SEM) in the Healthcare sector with a Hold rating and a price target of $ 27 (1 day ago). 

Click for full story >>
--------------------------------------------------------------------------

Royalty Pharma
Symbol: RPRX
Recent Price: $$41.36
Average Analyst Price Target: $51.75 (25.12%)
Market Cap: $$18.00B
Expected Ex-Dividend Date: May 19 2022
Expected Payment Date: Jun 15 2022
Expected Dividend & Yield: 1.80%

Recent Analyst Action: Adam Buckham, analyst at Scotiabank, reiterates coverage on Royalty Pharma (RPRX) in the Healthcare sector with a Buy rating and a price target of $ 53 (5 days ago). 

Click for full story >>
--------------------------------------------------------------------------